Colorectal Cancer
We recommend
Benefit of Adding Panitumumab to Maintenance Therapy in mCRC with Non-mutated RAS Oncogene
PANAMA was the first randomized study evaluating the addition of an anti-EGFR antibody to maintenance therapy with fluorouracil and folic acid (FU/FA) in patients with previously untreated metastatic colorectal cancer (mCRC) with a non-mutated (wt − wild-type) RAS oncogene. The results suggest that upon achieving disease control after initial treatment with FOLFOX + panitumumab, the combination of panitumumab with FU/FA might be the most suitable for maintenance therapy.
Combination of Targeted Therapy with Chemo in 1st Line in Patients with Left-Sided wtRAS mCRC
The preferred targeted therapy added to the combination with standard chemotherapy (CHT) for…
Early Tumor Regression as a Marker of Overall Survival in First-Line Treatment of mCRC
In the treatment of metastatic colorectal cancer (mCRC), prognostic factors besides overall…
Articles on this topic
Biochemotherapy of Aggressive Rectal Carcinoma – A Case Study from the Czech Republic
Colorectal cancer arises from a complex interplay of environmental and lifestyle factors…
Overall Survival in Patients with Metastatic CRC During 1st-Line Anti-EGFR Treatment Depending on the Presence or Absence of Hypomagnesemia
Hypomagnesemia is one of the side effects of monoclonal antibody therapy against the epidermal…
Successful Resection of a Rectosigmoid Tumor After Long-term Induction Biochemotherapy – A Case Report
Neoadjuvant treatment (chemoradiotherapy) for colorectal cancer is regularly used in advanced…
Treatment of a patient with colorectal cancer after kidney transplantation – case report
Patients after organ transplantation currently live to an older age thanks to advances in…
Prognostic Significance of the Location of Colorectal Cancer Metastases
An Austrian study presented at the ESMO 2020 conference analyzed the relationship between the…
Does the emergence of resistance to cetuximab mean ineffectiveness of all anti-EGFR antibodies?
Colorectal cancer (CRC) cells respond to targeted therapy in different ways. Besides the…
Efficacy of Panitumumab in the Treatment of Refractory mCRC
A meta-analysis of 7 clinical trials showed that panitumumab therapy demonstrates a higher…
Does Intense Monitoring After Colorectal Cancer Resection Bring Benefits?
Is it necessary to intensely monitor patients with colorectal cancer after curative resection?…
INTERACTIVE CASE STUDY of a patient with mCRC treated long-term with various modalities
MUDr. Stanislav John, Ph.D.,
Clinic of Oncology and Radiotherapy, Faculty of Medicine, Charles...
Dysregulation of microRNA Expression After Treatment with Anti-EGFR Antibodies
A team of researchers from Plzeň decided to verify whether treatment with anti-EGFR antibodies…
Subscribe
E-courses on this topic
Most read on this topic
Journal on this topic
Related topic
Interesting links
E-courses on this topic
Most read on this topic
- Successful Resection of a Rectosigmoid Tumor After Long-term Induction Biochemotherapy – A Case Report
- INTERACTIVE CASE STUDY of a patient with mCRC treated long-term with various modalities
- Biochemotherapy of Aggressive Rectal Carcinoma – A Case Study from the Czech Republic
- Early Tumor Regression as a Marker of Overall Survival in First-Line Treatment of mCRC
- Combination of Targeted Therapy with Chemo in 1st Line in Patients with Left-Sided wtRAS mCRC
- Prognostic Significance of the Location of Colorectal Cancer Metastases
Journal on this topic
Related topic
Interesting links